MarketCapExport financials
Laboratory Corporation of America Holdings (LH)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Laboratory Corporation of America Holdings Income Statement 2025-2006 | LH
Brief overview of revenue and earnings at Laboratory Corporation of America Holdings
The overview follows changes across a five-year period. Revenue at Laboratory Corporation of America Holdings moved from $14 billion in 2020 to $14 billion in 2025. Overall revenue changed by −0.2%, equal to an annualized rate of about −0%. Revenue was effectively stagnant over the period.
Gross profit was 5 billion dollars at the start and 4 billion dollars at the end of the period (−19%). The cost base moved against the top-line trend and weighed on the gross result. Gross margin moved from 35.4% to 28.8%. The business retained less gross profit from each unit of revenue.
EBITDA changed from $3.1 billion to $2.1 billion (−32.7%). EBITDA lagged revenue, showing weaker operating momentum. At the operating-margin level, the figure shifted from 22% to 14.8%. A lower EBITDA share weakens the quality of the result.
The net result moved from 1.6 billion dollars to 876 million dollars, or −43.7%. The decline reduces the quality of the financial trajectory.
The five-year change in capitalization reached +2.3%: from 23.3 billion dollars to 23.9 billion dollars. Market value followed a broadly neutral trajectory.
Summary assessment
The financial trajectory is weak and requires a cautious interpretation. The overall view is constrained by declining net profitability, a declining EBITDA margin and a lower gross margin. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement Laboratory Corporation of America Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
23.9 B | 21.1 B | 18.8 B | 21.7 B | 25.3 B | 23.3 B | 17.5 B | 14 B | 18.2 B | 13.6 B | 11.1 B | 9.73 B | 7.63 B | 8.39 B | 8.89 B | 6.64 B | 5.71 B | 7.05 B | - | - |
Shares |
83.2 M | 83.9 M | 87.1 M | 91.1 M | 93.1 M | 97.3 M | 97.9 M | 101 M | 102 M | 102 M | 98.8 M | 84.8 M | 85.7 M | 93.5 M | 97.8 M | 103 M | 107 M | 110 M | - | - |
Historical Prices |
287 | 252 | 216 | 239 | 271 | 240 | 176 | 148 | 173 | 142 | 110 | 123 | 93.5 | 88.6 | 89.9 | 64.4 | 53.2 | 64.2 | 68.5 | 51.5 |
Net Income |
877 M | 746 M | 418 M | 1.28 B | 2.38 B | 1.56 B | 824 M | 884 M | 1.27 B | 732 M | 437 M | 511 M | 574 M | 583 M | 520 M | 558 M | 543 M | 464 M | 477 M | - |
Revenue |
14 B | 13 B | 12.2 B | 11.9 B | 13.1 B | 14 B | 11.6 B | 11.3 B | 10.4 B | 9.64 B | 8.68 B | 6.01 B | 5.81 B | 5.67 B | 5.54 B | - | - | - | - | - |
Cost of Revenue |
9.94 B | 9.38 B | 8.8 B | 8.16 B | 8.14 B | 9.03 B | 8.3 B | 8.16 B | 7.22 B | 6.7 B | 5.78 B | 3.81 B | 3.59 B | 3.42 B | 3.27 B | 2.91 B | 2.72 B | 2.63 B | 2.38 B | - |
Gross Profit |
4.01 B | 3.62 B | 3.36 B | 3.71 B | 4.99 B | 4.95 B | 3.25 B | 3.18 B | 3.46 B | 3.18 B | 2.9 B | 2.2 B | 2.22 B | 2.25 B | 2.27 B | 2.1 B | 1.97 B | 1.87 B | 1.69 B | - |
Operating Income |
1.38 B | 1.09 B | 726 M | 1.44 B | 3.05 B | 2.45 B | 1.33 B | 1.33 B | 1.31 B | 1.27 B | 997 M | 910 M | 991 M | 1.02 B | 948 M | 979 M | 936 M | 843 M | 777 M | - |
Interest Expense |
224 M | 208 M | 200 M | 180 M | 212 M | 207 M | 241 M | 244 M | 235 M | 219 M | 275 M | 110 M | 96.5 M | 94.5 M | 87.5 M | 70 M | 62.9 M | -72 M | -56.6 M | - |
EBITDA |
2.07 B | 1.73 B | 1.3 B | 1.97 B | 3.63 B | 3.07 B | 1.63 B | 1.61 B | 1.65 B | 1.55 B | 1.28 B | 1 B | 1.09 B | 1.14 B | 1.12 B | 1.18 B | 1.13 B | 1.02 B | 940 M | - |
Operating Expenses |
- | - | - | - | - | - | 1.87 B | 1.8 B | 2.03 B | 1.81 B | 1.79 B | 1.27 B | 1.21 B | 1.2 B | 1.25 B | - | - | - | - | - |
General and Administrative Expenses |
2.22 B | 2.23 B | 2.02 B | 1.76 B | 1.69 B | 1.73 B | - | - | - | - | - | - | - | - | - | 1.03 B | 959 M | 935 M | 809 M | - |
All numbers in USD currency
Quarterly Income Statement Laboratory Corporation of America Holdings
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q3 | 2009-Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
81.7 M | 82.3 M | 83.1 M | 83.4 M | 83.6 M | 83.4 M | 84 M | 84.1 M | 84.1 M | 83.9 M | 86.6 M | 88.7 M | 88.4 M | 88.2 M | 90.2 M | 92.3 M | 93.2 M | 93.1 M | 96.3 M | 97.4 M | 97.6 M | 97.5 M | 97.4 M | 97.3 M | 97.2 M | 97.2 M | 97.6 M | 98.1 M | 98.6 M | 98.9 M | 102 M | 102 M | 102 M | 102 M | 102 M | 102 M | 102 M | 103 M | 103 M | 102 M | 102 M | 101 M | 101 M | 101 M | 91.9 M | 84.6 M | 84.9 M | 84.7 M | 84.8 M | 85.7 M | 89.2 M | 92 M | 92.9 M | 93.5 M | 89.2 M | 92 M | 92.9 M | 97.8 M | 101 M | 101 M | 100 M | 102 M | 104 M | 104 M | 106 M | 109 M |
Net Income |
299 M | 278 M | 261 M | 238 M | 213 M | - | 169 M | 205 M | 228 M | - | 183 M | 189 M | 213 M | - | 353 M | 359 M | 492 M | - | 587 M | 467 M | 770 M | - | 703 M | 232 M | 770 M | 227 M | -317 M | 190 M | 186 M | 158 M | 319 M | 234 M | 173 M | 688 M | 172 M | 185 M | 183 M | 184 M | 180 M | 204 M | 164 M | 110 M | 155 M | 170 M | 3 M | 120 M | 137 M | 141 M | 511 M | 126 M | 148 M | 152 M | 147 M | 120 M | 148 M | 152 M | 147 M | 135 M | 134 M | 123 M | 127 M | 140 M | 154 M | 133 M | 131 M | 136 M |
Revenue |
3.73 B | 3.54 B | 3.56 B | 3.53 B | 3.35 B | - | 3.28 B | 3.22 B | 3.18 B | - | 3.06 B | 3.03 B | 3.04 B | - | 2.87 B | 2.92 B | 3.9 B | - | 4.06 B | 3.84 B | 4.16 B | - | 3.9 B | 2.77 B | 2.82 B | 2.95 B | 2.93 B | 2.88 B | 2.79 B | 2.79 B | 2.83 B | 2.87 B | 2.85 B | 2.7 B | 2.6 B | 2.5 B | 2.41 B | 2.39 B | 2.37 B | 2.38 B | 2.3 B | 2.24 B | 2.27 B | 2.22 B | 1.77 B | 1.51 B | 1.55 B | 1.52 B | 1.43 B | 1.44 B | 1.46 B | 1.47 B | 1.44 B | 1.41 B | 1.42 B | 1.42 B | 1.42 B | 1.37 B | 1.4 B | 1.4 B | 1.37 B | - | - | - | - | - |
Cost of Revenue |
2.62 B | 2.52 B | 2.54 B | 2.48 B | 2.4 B | - | 2.38 B | 2.29 B | 2.28 B | - | 2.21 B | 2.19 B | 2.19 B | - | 1.98 B | 1.98 B | 2.67 B | - | 2.68 B | 2.58 B | 2.56 B | - | 2.34 B | 2.01 B | 2.1 B | - | 2.11 B | 2.06 B | 2 B | - | 2.04 B | 2.03 B | 2.07 B | - | 1.84 B | 1.75 B | 1.7 B | - | 1.63 B | 1.6 B | 1.59 B | - | 1.55 B | 1.5 B | 1.17 B | - | 981 M | 948 M | 3.81 B | - | 915 M | 891 M | 869 M | - | 863 M | 844 M | 847 M | - | 836 M | 815 M | 800 M | 749 M | 705 M | 687 M | 687 M | 681 M |
Gross Profit |
1.11 B | 1.01 B | 1.03 B | 1.05 B | 948 M | - | 904 M | 926 M | 897 M | - | 851 M | 842 M | 850 M | - | 886 M | 942 M | 1.23 B | - | 1.39 B | 1.26 B | 1.6 B | - | 1.56 B | 760 M | 728 M | 821 M | 817 M | 825 M | 790 M | 772 M | 790 M | 835 M | 779 M | 817 M | 784 M | 778 M | 712 M | 788 M | 788 M | 827 M | 777 M | 741 M | 765 M | 773 M | 625 M | 546 M | 571 M | 569 M | 2.2 B | 526 M | 548 M | 577 M | 572 M | 538 M | 556 M | 580 M | 576 M | 550 M | 568 M | 588 M | 568 M | 528 M | 534 M | 507 M | 498 M | 507 M |
Operating Income |
452 M | 381 M | 397 M | 394 M | 326 M | - | 254 M | 295 M | 321 M | - | 252 M | 266 M | 330 M | - | 374 M | 429 M | 688 M | - | 767 M | 704 M | 1.06 B | - | 1.05 B | 298 M | -193 M | 336 M | 340 M | 336 M | 318 M | 308 M | 343 M | 369 M | 305 M | 331 M | 327 M | 330 M | 318 M | - | 324 M | 366 M | 300 M | - | 308 M | 323 M | 132 M | - | 241 M | 247 M | 904 M | - | 245 M | 269 M | 262 M | - | 245 M | 276 M | 287 M | - | 239 M | 226 M | 236 M | 235 M | 270 M | 234 M | 235 M | 245 M |
Interest Expense |
61.1 M | 55.1 M | 56 M | 57.1 M | 56 M | - | 50.4 M | 47.6 M | 46.9 M | - | 50.3 M | 49.8 M | 50.7 M | - | 46.3 M | 42.3 M | 42.2 M | - | 42.2 M | 78.3 M | 48.5 M | - | 51.4 M | 52.7 M | 55 M | - | 60.5 M | 59.1 M | 56.7 M | - | 59.4 M | 63.1 M | 63.5 M | - | 59.9 M | 55 M | 52.4 M | - | 58.2 M | 53.5 M | 54.5 M | - | 55.9 M | 57.9 M | 104 M | - | 25.9 M | 25.8 M | 110 M | - | 24.7 M | 23.1 M | 24.5 M | - | 24.1 M | 21.3 M | 21.5 M | - | 20.3 M | 21 M | 24 M | -21.6 M | -14.5 M | -14.6 M | -15 M | -16.2 M |
EBITDA |
804 M | 554 M | 466 M | 463 M | 493 M | - | 318 M | 357 M | 476 M | - | 308 M | 318 M | 472 M | - | 423 M | 479 M | 849 M | - | 1.32 B | 796 M | 1.24 B | - | 1.49 B | 586 M | -48 M | 336 M | 761 M | 613 M | 454 M | 308 M | 758 M | 650 M | 448 M | 331 M | 715 M | 585 M | 446 M | - | 693 M | 613 M | 422 M | - | 648 M | 543 M | 235 M | - | 423 M | 370 M | 1.15 B | - | 415 M | 382 M | 318 M | - | 416 M | 389 M | 344 M | - | 413 M | 342 M | 294 M | 386 M | 371 M | 284 M | 380 M | 340 M |
General and Administrative Expenses |
577 M | 551 M | 552 M | 579 M | 546 M | - | 569 M | 558 M | 508 M | - | 526 M | 506 M | 457 M | - | 453 M | 432 M | 464 M | - | 520 M | 459 M | 430 M | - | 420 M | 396 M | 396 M | - | 402 M | 415 M | 394 M | - | 382 M | 395 M | 397 M | - | 381 M | 358 M | 343 M | - | 400 M | 409 M | 414 M | - | 386 M | 390 M | 442 M | - | 306 M | 298 M | 1.2 B | - | 279 M | 281 M | 283 M | - | 285 M | 280 M | 271 M | - | 284 M | 323 M | 283 M | 270 M | 245 M | 246 M | 247 M | 237 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Laboratory Corporation of America Holdings (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Diagnostics research industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
CareDx, Inc
CDNA
|
$ 54.31 | 0.32 % | $ 2.89 B |  USA |
 |
Celcuity
CELC
|
$ 79.99 | 0.12 % | $ 3.74 B | USA |
 |
Co-Diagnostics
CODX
|
$ 1.1 | 1.85 % | $ 1.46 M | USA |
 |
Castle Biosciences
CSTL
|
$ 34.88 | 0.09 % | $ 1.01 B | USA |
 |
Danaher Corporation
DHR
|
$ 221.56 | 0.21 % | $ 158 B | USA |
 |
DexCom
DXCM
|
$ 87.73 | 0.21 % | $ 34.2 B | USA |
 |
Fulgent Genetics
FLGT
|
$ 21.27 | 0.51 % | $ 655 M | USA |
 |
Guardant Health
GH
|
$ 176.31 | 0.27 % | $ 22.1 B | USA |
 |
Heska Corporation
HSKA
|
- | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
$ 163.9 | 0.2 % | $ 12.9 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
$ 522.02 | 0.1 % | $ 42 B | USA |
 |
IQVIA Holdings
IQV
|
$ 267.86 | 0.41 % | $ 46 B | USA |
 |
Anixa Biosciences
ANIX
|
$ 2.75 | 3.33 % | $ 89.2 K | USA |
 |
Lantheus Holdings
LNTH
|
$ 99.97 | 0.01 % | $ 6.75 B | USA |
 |
Medpace Holdings
MEDP
|
$ 617.15 | 0.23 % | $ 17.8 B | USA |
 |
Mettler-Toledo International
MTD
|
$ 1 492.34 | 0.11 % | $ 30.8 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
$ 4.01 | 0.62 % | $ 371 M | USA |
 |
ENDRA Life Sciences
NDRA
|
$ 6.5 | 4.33 % | $ 5.12 M | USA |
 |
NeoGenomics
NEO
|
$ 18.36 | 0.03 % | $ 2.35 B | USA |
 |
Neogen Corporation
NEOG
|
$ 13.57 | 2.72 % | $ 2.95 B | USA |
 |
Natera
NTRA
|
$ 390.79 | 0.41 % | $ 53.4 B | USA |
 |
Biomerica
BMRA
|
$ 2.61 | 0.36 % | $ 7.61 M | USA |
 |
OPKO Health
OPK
|
$ 1.7 | 0.29 % | $ 1.28 B | USA |
 |
RadNet
RDNT
|
$ 73.21 | 0.11 % | $ 5.5 B | USA |
 |
Sotera Health Company
SHC
|
$ 18.29 | 0.45 % | $ 5.19 B | USA |
 |
Neuronetics
STIM
|
$ 2.88 | 0.21 % | $ 190 M | USA |
 |
Trinity Biotech plc
TRIB
|
$ 7.01 | 0.68 % | $ 2.52 B | Irlanda |
 |
Twist Bioscience Corporation
TWST
|
$ 158.47 | 0.93 % | $ 9.48 B | USA |
 |
Biodesix
BDSX
|
$ 29.29 | 4.05 % | $ 221 M | USA |
 |
VolitionRx Limited
VNRX
|
$ 0.25 | 2.99 % | $ 31.4 M |  Singapore |
 |
Waters Corporation
WAT
|
$ 420.57 | 0.52 % | $ 25 B | USA |
 |
Exagen
XGN
|
$ 8.55 | 1.39 % | $ 184 M | USA |
 |
Syneos Health
SYNH
|
- | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K |  Israel |
 |
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M |  Britain |
 |
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | USA |
 |
Psychemedics Corporation
PMD
|
- | -1.84 % | $ 15.3 M | USA |
 |
Quotient Limited
QTNT
|
- | -11.32 % | $ 1.1 M | Schweiz |
 |
T2 Biosystems
TTOO
|
- | -39.35 % | $ 313 K | USA |
 |
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | USA |
 |
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | USA |
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
$ 1.7 | 0.55 % | $ 9.26 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
$ 15.08 | 11.68 % | $ 162 M |  China |
 |
Bioventus
BVS
|
$ 13.61 | 2.55 % | $ 907 M | USA |
 |
Brainsway Ltd.
BWAY
|
$ 13.45 | 0.88 % | $ 457 M | Israel |